Results 1 to 10 of about 138,605 (194)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma [PDF]

Frontiers in Cell and Developmental Biology, 2020
Histone deacetylases (HDACs) are enzymes that play a key role in regulating gene expression by remodeling chromatin structure. An imbalance of histone acetylation caused by deregulated HDAC expression and activity is known to promote tumor progression in
Monica Phimmachanh, Jeremy Z. R. Han, Yolande E. I. O’Donnell, Sharissa L. Latham, Sharissa L. Latham, David R. Croucher, David R. Croucher   +6 more
doaj   +4 more sources

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

Advanced Biomedical Research, 2019
Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation.
Masumeh Sanaei, Fraidoon Kavoosi
doaj   +2 more sources

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives

Experimental Hematology & Oncology
Histone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category have received approval from the U.S.
Jingjing Pu, Ting Liu, Xuzhen Wang, Amit Sharma, Ingo G. H. Schmidt-Wolf, Liping Jiang, Jian Hou   +6 more
doaj   +2 more sources

Histone Deacetylase Inhibitors as Anticancer Drugs

International Journal of Molecular Sciences, 2017
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone ...
Marie Stiborova, Tomáš Eckschlager, Jan Hraběta   +2 more
exaly   +2 more sources

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma [PDF]

Frontiers in Oncology, 2023
This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the ...
Omar Selim, Clara Song, Amy Kumar, Rebecca Phelan, Arun Singh, Noah Federman, Noah Federman, Noah Federman   +7 more
doaj   +2 more sources

Zinc binding groups for histone deacetylase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2018
Zinc binding groups (ZBGs) play a crucial role in targeting histone deacetylase inhibitors (HDACIs) to the active site of histone deacetylases (HDACs), thus determining the potency of HDACIs.
Qixiao Jiang
exaly   +2 more sources

Role of histone deacetylase inhibitors in non-neoplastic diseases [PDF]

Heliyon
Background: Epigenetic dysregulation has been implicated in the development and progression of a variety of human diseases, but epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules ...
Chunxiao Zhou, Dengke Zhao, Chunyan Wu, Zhimin Wu, Wen Zhang, Shilv Chen, Xindong Zhao, Shaoling Wu   +7 more
doaj   +2 more sources

Pharmacogenomics and histone deacetylase inhibitors. [PDF]

Pharmacogenomics, 2016
The histone deacetylase inhibitor valproic acid (VPA) has been used for many decades in neurology and psychiatry. The more recent introduction of the histone deacetylase inhibitors (HDIs) belinostat, romidepsin and vorinostat for treatment of hematological malignancies indicates the increasing popularity of these agents.
A. Goey, T. Sissung, C. Peer, W. Figg
semanticscholar   +3 more sources

Histone deacetylase inhibitors for leukemia treatment: current status and future directions [PDF]

European Journal of Medical Research
Leukemia remains a major therapeutic challenge in clinical oncology. Despite significant advancements in treatment modalities, leukemia remains a significant cause of morbidity and mortality worldwide, as the current conventional therapies are ...
Mohammad-Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, Yosra Vaez-Gharamaleki, Mahsa Akbarzadeh   +4 more
doaj   +2 more sources

Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review [PDF]

Frontiers in Oncology
Acute lymphocytic leukemia is a hematological malignancy that primarily affects children. Long-term chemotherapy is effective, but always causes different toxic side effects.
Yingjun Zhang, Yingjun Zhang, Ge Zhang, Ge Zhang, Yuefang Wang, Yuefang Wang, Lei Ye, Lei Ye, Luyun Peng, Luyun Peng, Rui Shi, Rui Shi, Siqi Guo, Siqi Guo, Jiajing He, Jiajing He, Hao Yang, Hao Yang, Qingkai Dai, Qingkai Dai   +19 more
doaj   +2 more sources